A mild phenoxysilyl linker for self-immolative release of antibody-drug conjugates

被引:4
|
作者
Wei, Ding [1 ,2 ,3 ]
Mao, Yurong [2 ,3 ]
Wang, Huihui [2 ,3 ]
Qu, Siqi [2 ,3 ]
Chen, Jiakang [2 ]
Li, Jiusheng [1 ]
Jiang, Biao [2 ]
Chen, Hongli [2 ]
机构
[1] Chinese Acad Sci, Shanghai Adv Res Inst, Shanghai 201210, Peoples R China
[2] ShanghaiTech Univ, Shanghai Inst Adv Immunochem Studies, Shanghai 201210, Peoples R China
[3] Univ Chinese Acad Sci, Beijing 100049, Peoples R China
关键词
Antibody-drug conjugates; Self-immolative release; Phenoxysilyl linker; Combretastatin A4 (CA4); DELIVERY; ACTIVATION; PAYLOADS; DESIGN;
D O I
10.1016/j.cclet.2022.108091
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Self-immolative linkers have been widely used to construct prodrugs to improve their efficacy and safety. In this study, we report the use of phenoxysilyl linker as a self-immolative unit to prepare antibody-drug conjugates (ADCs). Phenoxysily based ADC Ate-PPS-CA4 was prepared and its release was systematically investigated by mass spectrometry. Biological evaluation showed that Ate-PPS-CA4 displayed the ability to target delivery and self-immolative release the active payload CA4 on PD-L1 positive cells MDA-MB-231. As the same with its payload CA4, it could arrest the cell cycle to the G2/M phase and induced changes in cell morphology at the dose of its IC50. The development of this linker with novel drug release mechanisms will expand the methodology to construct ADCs, especially for non-internalizing ADCs by extracellular cleavage.(c) 2023 Published by Elsevier B.V. on behalf of Chinese Chemical Society and Institute of Materia Medica, Chinese Academy of Medical Sciences.
引用
收藏
页数:5
相关论文
共 50 条
  • [41] Intracellular Self-Immolative Polyprodrug with Near-Infrared Light Guided Accumulation and in Vivo Visualization of Drug Release
    Cheng, Dong-Bing
    Zhang, Xue-Hao
    Chen, Si-Yi
    Xu, Xiao-Xue
    Wang, Hao
    Qiao, Zeng-Ying
    ADVANCED MATERIALS, 2022, 34 (09)
  • [42] An FDA oncology analysis of antibody-drug conjugates
    Saber, Haleh
    Leighton, John K.
    REGULATORY TOXICOLOGY AND PHARMACOLOGY, 2015, 71 (03) : 444 - 452
  • [43] Antibody-drug conjugates: What drives their progress?
    Pander, Giulia
    Uhl, Philipp
    Kuehl, Nikos
    Haberkorn, Uwe
    Anderl, Jan
    Mier, Walter
    DRUG DISCOVERY TODAY, 2022, 27 (10)
  • [44] Antibody-Drug Conjugates-Evolution and Perspectives
    Chis, Adriana Aurelia
    Dobrea, Carmen Maximiliana
    Arseniu, Anca Maria
    Frum, Adina
    Rus, Luca-Liviu
    Cormos, Gabriela
    Georgescu, Cecilia
    Morgovan, Claudiu
    Butuca, Anca
    Gligor, Felicia Gabriela
    Vonica-Tincu, Andreea Loredana
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (13)
  • [45] Current approaches for the purification of antibody-drug conjugates
    Matsuda, Yutaka
    JOURNAL OF SEPARATION SCIENCE, 2022, 45 (01) : 27 - 37
  • [46] Investigational antibody-drug conjugates for hematological malignancies
    Polson, Andrew G.
    Ho, William Y.
    Ramakrishnan, Vanitha
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2011, 20 (01) : 75 - 85
  • [47] Incorporation of a self-immolative spacer enables mechanically triggered dual payload release
    Tseng, Yu-Ling
    Zeng, Tian
    Robb, Maxwell J.
    CHEMICAL SCIENCE, 2024, 15 (04) : 1472 - 1479
  • [48] Fate of Antibody-Drug Conjugates in Cancer Cells
    Cécile Chalouni
    Sophia Doll
    Journal of Experimental & Clinical Cancer Research, 37
  • [49] Non-internalising antibody-drug conjugates
    Ashman, Nicola
    Bargh, Jonathan D.
    Spring, David R.
    CHEMICAL SOCIETY REVIEWS, 2022, 51 (22) : 9182 - 9202
  • [50] Click chemistry in the synthesis of antibody-drug conjugates
    Dudchak, Rostyslav
    Podolak, Magdalena
    Holota, Serhii
    Szewczyk-Roszczenko, Olga
    Roszczenko, Piotr
    Bielawska, Anna
    Lesyk, Roman
    Bielawski, Krzysztof
    BIOORGANIC CHEMISTRY, 2024, 143